Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Medivolve Inc MEDVF

Medivolve, Inc. is a Canada-based healthcare technology company. The Company has two business units: Medivolve Pharmacy Division (MPD) and Collection Sites Diagnostics (CSD). MPD provides retail pharmacy and mail-order pharmacy services related to COVID-19, antibiotics, dermatology, family medicine, immunology, neurology, pain management, pediatrics, preventive medicine, and psychiatry to... see more

OTCPK:MEDVF - Post Discussion

Medivolve Inc > SERIOUS TRUST DEFICIT EXIST Between company and shareholders
View:
Post by Hiddensecrets on Apr 11, 2021 4:41pm

SERIOUS TRUST DEFICIT EXIST Between company and shareholders

The stock price of 18 cents per share for MEDV confirms the DISTRUST that shareholders have for the company, which presumably has $ 27 million in sales in 2 quarters.

If there was trust we would be at $ 1 per share. 

This is how the TRUST was broken with shareholders

(a) Shareholders are told of the possible  UPS in business but are never warned of the possible downs in business.

(b) Shareholdes are promised possible discount receivavle financing and, are given dilution shares at a 50% discount

(c) Shareholders are promised 2,000 cubes and, will only receive a possible 60.

(d) Shareholders are promised a possible 160 tests per day per cube and, reality at tops the average is 50 tests per day over 3 month period.

(e) Shareholders are told that shares will be issued to buy a telehealth company, only to learn that this company was just created (it was a shell company)

(f) Shareholders are told tests are tracking better in March 2021 than February 2021, actual results show the reverse being a material decline.

(g) Shareholders are told that companies are approaching them every day for covid19 testing and, yet we do not have any signed company deals for covid19 announced except for gold company in January 2021.

(h) Shareholders are told in various press releases that acquistions and investments are made BUT at year-end financials it is shown as material write-downs to nil value.

(i) Flip flopping on transparency in tests and, changing of metrics.  At one point company refused to release test results as they claimed that you would not understand them, and then they changed metrics to value their performance. with other metrics as first set of metrics did not suit them.

(j) Key person running Collection sites suddenly steps down, no reason given.

(k) Canaccord shareholders are given a lucrative bought deal, only to find out 2 months later that they overpaid and that there was no lucrative deal. 


So you tell me, HOW IS THE COMPANY going to overcome the TRUST DEFICIT?

I just wish I had sold at 70 cents, my fault, got too greedy and this trust deficit was well hidden at that time. 

mpo

Comment by Abovetheflay on Apr 12, 2021 11:12am
Hi Hidden manipulator.  You are trying to keep the price down with you posts, you talk trust and then constantly flip flop with your posts.  Bring value or stop posting.  You are so obvious in your efforts.  Say hi to the OSC when they get in touch with you...I hear that Medivolve is on the watch list and all posts are being reviewed and past posts.   You talk trust ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities